Kaplan Gilla insider trades
Kaplan Gilla has filed 21 Form 4s with the SEC that we hold, for Avalo Therapeutics, Inc. (AVTX) (Director) and Tyra Biosciences, Inc. (TYRA) (Director). Across all of them we count 0 purchases worth $0 and 6 sales worth $1.2M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($528.5K). The largest single trade was a sale of 14,295 shares of Tyra Biosciences, Inc. worth $528.5K, dated 2026-03-25. The first filing on our record is dated 2021-07-02 and the latest 2026-06-04.
Avalo Therapeutics, Inc. (AVTX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Tyra Biosciences, Inc. (TYRA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-06-12 | S, sale reported on Form 4 | 30,000 | $309.3K | 2025-06-16 |
| 2025-06-13 | S, sale reported on Form 4 | 15,000 | $154.7K | 2025-06-16 |
| 2025-06-16 | S, sale reported on Form 4 | 6,814 | $70.7K | 2025-06-16 |
| 2025-06-17 | S, sale reported on Form 4 | 10 | $104 | 2025-06-20 |
| 2025-06-18 | S, sale reported on Form 4 | 9,568 | $93.6K | 2025-06-20 |
| 2026-03-25 | S, sale reported on Form 4 | 14,295 | $528.5K | 2026-03-27 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1247024) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms